Regencell Shares Retreat After 17.39% Rally as Annual Loss Widens

Hong Kong-based Regencell Bioscience Holdings Limited (Nasdaq: RGC) closed at $9.52 on Thursday, Oct. 15, up $1.41, or 17.39%, from $8.11 a day earlier. The shares ended lower in the next session. Regencell filed its fiscal 2026 annual report on Oct. 7, covering the year ended June 30. The company reported a net loss of $11.70 million, compared with $3.58 million a year earlier, and no product-sales revenue in either fiscal year. Its development program centers on Traditional Chinese Medicine formulas for attention-deficit/hyperactivity disorder and autism spectrum disorder. It had not applied for regulatory approval for those products as of the annual report. The filing also disclosed an ongoing U.S. Department of Justice (DOJ) investigation into trading in Regencell’s ordinary shares.

BeCrypto News shows a short excerpt and links to the publisher. The full report belongs to TokenPost.